Cargando…

Modeling and Simulation of the Pharmacokinetics and Target Engagement of an Antagonist Monoclonal Antibody to Interferon‐γ–Induced Protein 10, BMS‐986184, in Healthy Participants to Guide Therapeutic Dosing

BMS‐986184 is a human, second‐generation, anti–interferon‐γ–induced protein 10 (IP‐10) monoclonal antibody. In this study the pharmacokinetics and target engagement (TE) of BMS‐986184 in healthy participants were characterized using population‐based target‐mediated drug disposition (TMDD) modeling a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cai, Weiguo, Leil, Tarek A., Gibiansky, Leonid, Krishna, Murli, Zhang, Hongwei, Gu, Huidong, Sun, Huadong, Throup, John, Banerjee, Subhashis, Girgis, Ihab
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496395/ https://www.ncbi.nlm.nih.gov/pubmed/32068354 http://dx.doi.org/10.1002/cpdd.784

Ejemplares similares

Population Pharmacokinetic Analysis of BMS‐986166, a Novel Selective Sphingosine‐1‐Phosphate‐1 Receptor Modulator, and Exposure‐Response Assessment of Lymphocyte Counts and Heart Rate in Healthy Participants
por: Bihorel, Sébastien, et al.
Publicado: (2020)

Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors
por: Chimalakonda, Anjaneya, et al.
Publicado: (2021)

Lack of Electrocardiographic Effects of Deucravacitinib in Healthy Subjects
por: Chimalakonda, Anjaneya, et al.
Publicado: (2022)

Dapagliflozin: BMS 512148; BMS-512148
Publicado: (2012)

Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS‐986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo‐controlled trial in healthy participants
por: Catlett, Ian M., et al.
Publicado: (2020)

Crystal structures of trimeric HIV Env with entry inhibitors BMS-378806 and BMS-626529
por: Pancera, Marie, et al.
Publicado: (2017)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

BMS-986020, a Specific LPA(1) Antagonist, Provides Neuroprotection against Ischemic Stroke in Mice
por: Gaire, Bhakta Prasad, et al.
Publicado: (2020)

Construction of the MPI BMS Prototype Chamber
por: Bratzler, U, et al.
Publicado: (1997)

Population pharmacokinetic and exposure–response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia
por: Gibiansky, Ekaterina, et al.
Publicado: (2021)

BMS1 Is Mutated in Aplasia Cutis Congenita
por: Marneros, Alexander G.
Publicado: (2013)

LPA(1) antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis
por: Decato, Benjamin E., et al.
Publicado: (2022)

Role of Mitochondrial Toxicity in BMS-986094-Induced Toxicity
por: Feng, Joy Y., et al.
Publicado: (2017)

Effect of BMS-470539 on lipopolysaccharide-induced neutrophil activation
por: Lee, Seongheon, et al.
Publicado: (2020)

Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab‐refractory follicular lymphoma patients in the GADOLIN phase III study
por: Gibiansky, Ekaterina, et al.
Publicado: (2019)

Hedgehog Signaling Inhibition by Smoothened Antagonist BMS-833923 Reduces Osteoblast Differentiation and Ectopic Bone Formation of Human Skeletal (Mesenchymal) Stem Cells
por: AlMuraikhi, Nihal, et al.
Publicado: (2019)

Phase I study of the mitomycin C analogue BMS-181174.
por: Macaulay, V. M., et al.
Publicado: (1998)

Identification and Preclinical Pharmacology of the γ-Secretase Modulator BMS-869780
por: Toyn, Jeremy H., et al.
Publicado: (2014)

A Behaviour Monitoring System (BMS) for Ambient Assisted Living
por: Eisa, Samih, et al.
Publicado: (2017)

The effects of BMS-470539 on lipopolysaccharide-induced acute lung injury
por: Jang, Eun-A, et al.
Publicado: (2019)

Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants
por: Lee, Sun Ku, et al.
Publicado: (2017)

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
por: Bilusic, Marijo, et al.
Publicado: (2019)

Effects of Urotensin II Receptor Antagonist, GSK1440115, in Asthma
por: Portnoy, Alison, et al.
Publicado: (2013)

The Effectiveness and Adverse Events of Amitriptyline and Aripiprazole in Very Elderly Patients With BMS
por: Watanabe, Motoko, et al.
Publicado: (2022)

Quantitative Systems Pharmacology can reduce attrition and improve productivity in pharmaceutical research and development
por: Leil, Tarek A., et al.
Publicado: (2014)

Editorial: The emerging discipline of quantitative systems pharmacology
por: Leil, Tarek A., et al.
Publicado: (2015)

A phase I and pharmacokinetic study of novel taxane BMS-188797 and cisplatin in patients with advanced solid tumours
por: du Bois, A, et al.
Publicado: (2006)

Phase I single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of BMS-927711 in healthy subjects
por: Tong, G, et al.
Publicado: (2013)

Characterization of a BMS-181174-resistant human bladder cancer cell line.
por: Xia, H., et al.
Publicado: (1997)

Comparison of coronary DES and BMS in octogenarians: A systematic review and meta-analysis
por: Gao, Lei, et al.
Publicado: (2013)

Cases Reported by Surgeon R. D. Murray, M.B. B.M.S.
Publicado: (1878)

Identification and Preclinical Evaluation of the Bicyclic Pyrimidine γ-Secretase Modulator BMS-932481
por: Boy, Kenneth M., et al.
Publicado: (2019)

Structure-activity relationship of BMS906024 derivatives for Cryptosporidium parvum growth inhibition
por: Lee, Seungheon, et al.
Publicado: (2023)

Experience with Using the Sensewear BMS Sensor System in the Context of a Health and Wellbeing Application
por: Jones, Val, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_5evqetf5oqgjpuje530o1pb3uu